South San Francisco, CA, United States of America

Simon Mathieu

USPTO Granted Patents = 14 (Patent Applications = 4)

CIPO Patents = 2

EPO Patents = 7 (Patent Applications = 12)

Average Co-Inventor Count = 11.5

ph-index = 5

Forward Citations = 75(Granted Patents)

Location History:

San Francisco, CA (US) (2014)
Burlingame, CA (US) (2010 - 2016)
South San Francisco, CA (US) (2012 - 2018)

Company Filing History:

F. Hoffmann-la Roche Ag

where one patent can have more than one assignee

Years Active: 2010-2018

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9943519 - Pharmaceutical compounds (2018-04-17),

2. 9487533 - Phosphoinositide 3-kinase inhibitor compounds and methods of use (2016-11-08),

3. 8993563 - Phosphoinositide 3-kinase inhibitor compounds and methods of use (2015-03-31),

4. 8815877 - Serine/threonine kinase inhibitors (2014-08-26),

5. 8802670 - Pharmaceutical compounds (2014-08-12),

6. 8637537 - Serine/threonine kinase inhibitors (2014-01-28),

7. 8450315 - Phosphoinositide 3-kinase inhibitor compounds and methods of use (2013-05-28),

8. 8394795 - Pyrazole [3, 4-B] pyridine Raf inhibitors (2013-03-12),

9. 8383620 - Phosphoinositide 3-kinase inhibitor compounds and methods of use (2013-02-26),

10. 8338452 - Raf inhibitor compounds and methods of use thereof (2012-12-25),

11. 8158626 - Thiazolopyrimidine PI3K inhibitor compounds and methods of use (2012-04-17),

12. 7893059 - Thiazolopyrimidine PI3K inhibitor compounds and methods of use (2011-02-22),

13. 7888352 - Phosphoinositide 3-kinase inhibitor compounds and methods of use (2011-02-15),

14. 7846929 - Phosphoinositide 3-kinase inhibitor compounds and methods of use (2010-12-07),

Title: The Innovative Contributions of Simon Mathieu

Introduction

Simon Mathieu is a prominent inventor based in South San Francisco, CA. He has made significant contributions to the field of pharmaceutical compounds, holding a total of 14 patents. His work primarily focuses on developing compounds that inhibit lipid kinases, which are crucial in treating various disorders, including cancer.

Latest Patents

Among his latest patents are innovative pharmaceutical compounds that include compounds of Formulae Ia and their stereoisomers, geometric isomers, tautomers, solvates, metabolites, and pharmaceutically acceptable salts. These compounds are designed to inhibit lipid kinases, particularly PI3K, and are aimed at treating disorders mediated by these kinases. Additionally, he has developed methods for using these compounds for in vitro, in situ, and in vivo diagnosis, prevention, or treatment of such disorders in mammalian cells. Another notable patent involves phosphoinositide 3-kinase inhibitor compounds, which include compounds of Formulas Ia-d. These compounds are also useful for modulating the activity of lipid kinases and treating related disorders.

Career Highlights

Throughout his career, Simon Mathieu has worked with leading companies in the pharmaceutical industry, including Genentech, Inc. and F. Hoffmann-La Roche AG. His experience in these organizations has allowed him to contribute to groundbreaking research and development in the field of medicinal chemistry.

Collaborations

Simon has collaborated with several professionals in his field, including Janet Gunzner and Adrian Folkes. These collaborations have further enhanced his research and innovation capabilities.

Conclusion

Simon Mathieu's work in developing pharmaceutical compounds has made a significant impact on the treatment of disorders such as cancer. His innovative patents and collaborations with leading companies and professionals highlight his contributions to the field of medicinal chemistry.

This text is generated by artificial intelligence and may not be accurate.